Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Hematologic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Anemia, Refractory, with Excess of Blasts 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 131fludarabine phosphate 108Mycophenolic Acid 92Peripheral Blood Stem Cell Transplantation 91Whole-Body Irradiation 80Tacrolimus 78Busulfan 64Cyclosporine 60fludarabine 55Melphalan 55Filgrastim 54Antilymphocyte Serum 48Methotrexate 41Radiotherapy 39Etoposide 35Rituximab 33Granulocyte Colony-Stimulating Factor 27Sirolimus 25Cytarabine 23Stem Cell Transplantation 21Cord Blood Stem Cell Transplantation 21thymoglobulin 20Thiotepa 19Methylprednisolone 18sargramostim 17Cyclosporins 16Carmustine 16Alemtuzumab 16Therapeutics 13Psychiatric Rehabilitation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × Maraviroc × Other hematologic neoplasm × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡